Neuroendocrine Cancer Market Size, Competitive Landscape and Market Forecast - 2029

Global Neuroendocrine Cancer Market is segmented by Drug Type (Sunitinib Malate, Everolimus, Lanreotide, Octreotide, Others), By Treatment (Surgery, Chemotherapy, Targeted Therapy, Radiotherapy, Other Medications), By End-User (Hospitals, Oncology Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Neuroendocrine Cancer Market Size Growth 2022-2029

The Neuroendocrine Cancer Market size was valued at USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of % during the forecast period (2022-2029). Neuroendocrine tumors are tumors that start in specialized neuroendocrine cells. Nerve cells and hormone-producing cells share characteristics with neuroendocrine cells.

Report Key Highlights:

1. The increasing R&D is expected to drive the Neuroendocrine Cancer Market growth in the forecast period
2. The targeted therapy segment is expected to dominate the growth of the neuroendocrine cancer market
3. Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for the treatment of neuroendocrine cancer.
4. North America is projected to record the highest growth rate in the neuroendocrine cancer market over the forecast period 2022-2029, and the fastest-growing region is the Asia Pacific region.
5. Europe neuroendocrine cancer market is anticipated to continue its dominance in the global market during the forecast period 2022-2029
6. The market is classified into major regions such as North America, South America, Europe, Asia Pacific, the Middle East and Africa, and the Rest of the globe.

Market Dynamics

The factors influencing the global neuroendocrine cancer market are the increasing research and development, and the growing prevalence of neuroendocrine cancer.

Immunotherapy, also known as biologic therapy, is a type of treatment that aims to increase the body's natural defenses to combat a tumor. Researchers have tested new cancer vaccinations on NETs (Neuroendocrine Tumor Treatment). Another area of immunotherapy research is the development of medicines that block the protein PD-1. T cells, a white blood cell that aids the body's immune system in fighting disease, have PD-1 on their surface. Because PD-1 prevents the immune system from eliminating tumor cells, blocking it permits it to remove the disease more effectively.

Atezolizumab (Tecentriq), a PD-L1 inhibitor, has been approved by the FDA for treating metastatic small cell lung cancer in conjunction with carboplatin and etoposide chemotherapy (both of which are available as generic medicines). Although lung NETs are a distinct disease, the efficacy of atezolizumab highlights the need for further research into immunotherapy for patients with lung NETs. Also being investigated is chimeric antigen receptor treatment (CAR T-cell therapy) in combination with antibody-drug conjugates, a targeted therapy. CAR T-cell treatment involves removing a patient's T cells, which are part of their immune system, and reprogramming them to target cancer cells in the patient.

The T cells are then reintroduced to the patient. Moreover, on August 13th, 2021, Belzutifan (Welireg), a hypoxia-inducible factor inhibitor, was approved by the FDA for adult patients with von Hippel-Lindau disease who need treatment for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors but don't need surgery right away.

The side effects associated with the neuroendocrine cancer treatment are expected to hamper the market

Targeted therapy targets the tumor's unique genes, proteins, or tissue environment, all of which play a role in cancer growth and survival. This treatment inhibits tumor cell growth and spreads while limiting damage to healthy cells. The targets of all cancers are not the same. The US Food and Drug Administration (FDA) has approved Everolimus (Afinitor) for treating advanced NETs of the GI tract, lung, and pancreas.

This medicine targets the mTOR protein, which is essential for cell growth and survival. In some people, this medicine can help delay the growth of these tumors, but it seldom shrinks them. Some side effects include mouth sores, lowered blood counts, and exhaustion. Sunitinib (Sutent) is a targeted medication that inhibits the production of a protein known as VEGF. Angiogenesis, or the formation of new blood vessels, necessitates the presence of VEGF. The purpose of anti-angiogenesis medicines like sunitinib is to "starve" the tumor of nutrients given by blood vessels, which are required for it to develop and spread. The FDA has given it the approval to treat advanced pancreatic NETs. Diarrhea, nausea, vomiting, lethargy, and elevated blood pressure are common side effects of this medication.

In clinical studies, further targeted treatments for NETs are being investigated. Drugs that block the creation of new blood vessels or specific cancer cell survival pathways are among them.

Industry Analysis

The global neuroendocrine cancer market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, reimbursement scenario, pipeline analysis, pricing analysis, etc.

COVID-19 Impact Analysis

There have been particular concerns about the impact of the COVID-19 pandemic on specialized tumor services. Neuroendocrine tumor (NET) services are typically provided in a restricted number of centers and are highly specialized. Following COVID-19, the restoration of highly specialized NET services, as well as future service delivery and research funding, must take into account the extreme challenges faced during the pandemic. Hence, the neuroendocrine cancer market is expected to be impacted by covid-19.

Neuroendocrine Cancer Market Scope

Metrics	Details
Market Size Available	2022-2029
Segments Covered	By Drug Type, By Treatment, By End User, and By Region
Report Insights Covered	Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region	Asia Pacific
Largest Market Share	North America

Segment Analysis

Targeted medications differ from regular chemotherapy (chemo) drugs in their function. These medications are designed to target specific regions of cancer cells. They can be useful in situations when chemo isn't, and they frequently have distinct adverse effects than chemo. Pancreatic neuroendocrine tumors (NETs) are treated with targeted medications that prevent angiogenesis (the creation of new blood vessels that fuel malignancies) or critical proteins (called tyrosine kinases) in cancer cells that help them grow and survive.

Moreover,  sunitinib inhibits the formation of new blood vessels by blocking multiple tyrosine kinases. It has been demonstrated to assist in the slowing of tumor growth. This medication is used once a day as a tablet. Everolimus inhibits mTOR, a protein that typically aids cell growth and division. It has been demonstrated to be effective in treating advanced pancreatic NETs. Everolimus is a tablet that needs to be taken once a day.HIF inhibitors, such as Belzutifan, are a type of medication. It inhibits a protein known as hypoxia-inducible factor 2 alpha (HIF-2a), which is implicated in cancer cell development and tumor blood vessel creation. This medication is given as pills once a day. Belzutifan is a drug that can be used to treat persons with von Hippel-Lindau disease (VHL) who have a pancreatic NET but don't need surgery immediately or quickly.

Geographical Analysis

The North American region is expected to hold the largest market share in the global neuroendocrine cancer market

The increasing prevalence of neuroendocrine cancer and growing R&D are expected to drive the market growth. In the United States, it is estimated that about 12,000 people are diagnosed with a NET each year, with around 175,000 people living with this diagnosis. For years, the number of persons diagnosed with this tumor has been rising. Moreover, on January 26th, 2018, the US Food and Drug Administration approved Lutathera (lutetium Lu 177 dotatate) for treating gastroenteropancreatic neuroendocrine tumors, cancer involving the pancreas, or gastrointestinal tract (GEP-NETs). This is the first time a radioactive medicine, often known as a radiopharmaceutical, has been approved to treat GEP-NETs. Lutathera is for adults with GEP-NETs that are somatostatin receptor-positive.

Competitive Landscape

The global neuroendocrine cancer market is highly competitive with drug approvals, acquisitions, and product launches. Some of the key players in the market are Amgen, Inc, Bristol-Myers Squibb, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Ipsen Pharmaceuticals, Novartis AG, Pfizer Inc, Hutchinson Medipharma Limited, Tarveda Therapeutics, Progenics Pharmaceuticals.

Company Profile:

Amgen, Inc

Overview: Amgen Inc. is an American global biopharmaceutical corporation headquartered in Thousand Oaks, California. Amgen was founded in Thousand Oaks, California, in 1980 and is one of the world's largest independent biotechnology businesses.

Product Portfolio: DLL3 (Delta-like protein 3) is a protein that acts as an inhibitor.  In the lungs, the Notch pathway is essential for neuroendocrine versus epithelial cell differentiation and control. DLL3 is found in the Golgi apparatus, where it suppresses Notch 1 signaling.